JOHNSON & JOHNSON'S single-dose COVID vaccine was authorized in the European Union Thursday, the fourth shot greenlighted by the bloc.
AFP spoke to J&J's Chief Scientific Officer Paul Stoffels about what it means for the fight to end the pandemic. The interview was edited for clarity.
AFP: What makes the J&J vaccine such an important tool?
Stoffels: The vaccine we just got approved by the European authorities is a single-shot vaccine, and it's the first vaccine which was studied on a very large scale (around 40,000 people), including the variants. And we have shown high efficacy against severe disease as well as hospitalization and death.
In addition, it's a single dose with stability that you ship at 2 to 8 Celsius, normal refrigeration, which will help facilitate large-scale implementation in the world.
AFP: What's your response to criticism that J&J's shot isn't as protective as the RNA vaccines made by Pfizer and Moderna?
Stoffels: We did our study globally, on three continents: the US, South America, and South Africa, but also in very difficult circumstances in the surge of the pandemic.
We now know the efficacy of the vaccine on the variants, and also can show that independent of region, independent of variant, or of age, you protect against severe disease, death and hospitalization.
And that is 85 percent protection for severe disease, but also 100 percent so far, we have not seen after day 28 (any) people who are hospitalized or dead. That's the most important challenge in this disease.
AFP: J&J's vaccine uses a common-cold causing adenovirus, genetically-modified so it can't replicate, as a "vector" to carry the gene for a part of the coronavirus to human cells in order to train the immune system. What's the biological advantage of this approach?
Stoffels: We have a very decent antibody response, but cellular immunity is the one which makes it durable, but also broad spectrum.
We learned that already: we have done an Ebola vaccine, a Zika vaccine, and we're working on an HIV vaccine. The secret sauce of such a vaccine is the combination of both.
AFP: Can you explain in easy terms what cellular immunity is?
Stoffels: When you get vaccinated as a child, you get your vaccines, which protects you for your life.
So your body memory memorizes this pathogen, the disease agent.
Although for many of them, you will not measure antibodies anymore later on, your body still can react because it immediately knows 'This is a pathogen I've seen before.' And that's where cellular immunity is very important, both for the efficacy immediately but also for remembering for a long time.
AFP: What's the state of your studies for children and pregnant women?
Stoffels: At the moment, we are studying the vaccine in adolescents, that is ongoing, and that is 12 to 17 years. Phase 2 and 3 (when efficacy studies begin) for children below 12 years begins in April. Pregnant women will be studied beginning now.
AFP: Will you make variant specific vaccines?
Stoffels: Out of abundance of precaution, we started already making a vaccine based on the South African variant. We don't know whether we'll need it, but if it's needed, it's on the way, and we are at the moment during the early stages of upscaling.
AFP: Some scientists have raised concerns that repeating your vaccine will be a problem because the immune system will remember the virus used as a vector and attack it, reducing efficacy.
Would this pose a problem for boosters?
Stoffels: In our HIV vaccine work, we give people exposure to the vector four times over a year. Although we saw small changes, we did not see that we couldn't use it for a booster.
Ad26 (Adenovirus 26) as a vector, the one we have, was selected for low immunogenicity, as well as low presence in humans. We are reasonably comfortable that we can boost the vaccine without issue.
AFP: Is there anything else we should know?
Stoffels: We have a very comprehensive network in the world to make sure we can serve the entire world, as well as collaborations with Covax (the global vaccine initiative).
We hope that very quickly after what we're doing in the US and Europe, that we move to being able to vaccinate the entire world. And we have a big commitment at J&J to do this at a not for profit price.
ETX Studio
Fri Mar 12 2021
Syringes with doses of the Johnson & Johnson COVID-19 vaccine await recipients at a vaccination site at Baldwin Hills Crenshaw Plaza. ETXStudiopic
Who is Prabowo Subianto, incoming president of Indonesia?
A wealthy ex-general with ties to Indonesia's popular outgoing president and its dictatorial past, looks set to be its next leader.
Iran's supreme leader says Hamas leader's death will not halt 'Axis of Resistance'
The "Axis of Resistance", built up with years of Iranian support, includes Hamas, the Lebanese Hezbollah group, the Houthi movement in Yemen, and various Shi'ite groups in Iraq and Syria.
Putin says Russia willing to seek compromises between Iran and Israel
Russia is ready to help seek compromises between arch-foes Israel and Iran, President Vladimir Putin said on Friday, saying these would be difficult but possible.
What proposals will Russia push at the BRICS summit?
The proposal is also to establish a BRICS reinsurance company to allow uninterrupted shipment of goods and key commodities between members.
Indonesia's free meals plan in the spotlight as Prabowo readies for office
Prabowo calls the programme one of the main drivers of economic growth, eventually set to add an estimated 2.5 million jobs.
Astro AWANI's revamped English news website, AWANI International, launches on Oct 21
Astro AWANI's revamped English platform delivers in-depth global news and expert analysis to keep you informed on key developments.
Israeli strikes kill 33 people in Jabalia refugee camp in Gaza, medics say
Residents of Jabalia said Israeli tanks had reached the heart of the camp after pushing through suburbs and residential districts.
Liam Payne's ex-partner calls for media restraint after 'painful' death
Cheryl Tweedy used her statement to urge the media to remember they had a seven-year-old son, Bear, who could read the reports.
Analysts: Indonesia's strong MoF leadership team to boost investor confidence
Sri Mulyani Indrawati as head of Indonesia's Ministry of Finance is expected to instil confidence among investors.
Biden offers both a carrot and a stick to Israel as his term nears an end
Israel has frequently resisted US advice and has caused political difficulties for the Biden administration.
Putin says BRICS will generate most of global economic growth
Russian President Vladimir Putin will host a summit of the group in the city of Kazan on Oct. 22-24.
ISIS Malaysia's perspective of Budget 2025
An excellent rakyat-centric budget under the overarching principle of a caring and humane economy.
Budget 2025: Record increase in STR, SARA aid initiatives
The government will provide a significant boost to the Sumbangan Tunai Rahmah (STR) and Sumbangan Asas Rahmah (SARA) initiatives next year.
Budget 2025: EPF contributions to be made mandatory for foreign workers – PM Anwar
The government plans to make it compulsory for all non-citizen workers to contribute to the Employees Provident Fund (EPF).
What policies to expect from Indonesia's new President Prabowo
Prabowo will be open to foreign investment, his aide has said, such as by offering investors management of airports and sea ports.
Budget 2025: Govt allocates RM470 mil to empower women's participation in PMKS
The Women's Leadership Apprenticeship Program will be intensified as an effort to produce more female corporate personalities.
Israel sends more troops into north Gaza, deepens raid
Residents of Jabalia in northern Gaza said Israeli tanks had reached the heart of the camp, using heavy air and ground fire.
Indonesia ramps up security ahead of Prabowo's inauguration
Prabowo Subianto will be sworn in as Indonesia's president on Sunday with Vice President-elect, Gibran Rakabuming Raka, also taking office.
Immediate allocation of RM150 mil for local authorities, DID to tackle flash floods
Datuk Seri Anwar Ibrahim said this allocation is intended to address the recent flash floods that hit the capital and several major towns.
Budget 2025: Sabah, Sarawak to continue receiving among highest allocations - PM
Sabah and Sarawak continues to be prioritised under Budget 2025, with allocations of RM6.7 billion and RM5.9 billion respectively.